Valneva SE (INRLF)
- Previous Close
4.6200 - Open
4.6200 - Bid 4.0200 x 47300
- Ask 4.3600 x 40000
- Day's Range
4.6200 - 4.6200 - 52 Week Range
3.3500 - 8.5500 - Volume
100 - Avg. Volume
731 - Market Cap (intraday)
642.887M - Beta (5Y Monthly) 0.90
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2100 - Earnings Date Aug 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.
valneva.comRecent News: INRLF
Performance Overview: INRLF
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INRLF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INRLF
Valuation Measures
Market Cap
586.09M
Enterprise Value
624.24M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.83
Price/Book (mrq)
3.08
Enterprise Value/Revenue
3.75
Enterprise Value/EBITDA
150.47
Financial Highlights
Profitability and Income Statement
Profit Margin
-15.95%
Return on Assets (ttm)
-0.42%
Return on Equity (ttm)
-12.38%
Revenue (ttm)
152.96M
Net Income Avi to Common (ttm)
-24.39M
Diluted EPS (ttm)
-0.2100
Balance Sheet and Cash Flow
Total Cash (mrq)
176.64M
Total Debt/Equity (mrq)
111.86%
Levered Free Cash Flow (ttm)
-139.14M